Applied Molecular Transport logo
Applied Molecular Transport AMTI

Quarterly report 2023-Q3
added 11-09-2023

report update icon

Applied Molecular Transport Total Assets 2011-2026 | AMTI

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.
Main categories of assets
Current assets (used within one year):
  • Cash and cash equivalents
  • Accounts receivable (amounts owed by customers)
  • Inventory of goods, raw materials, and supplies
  • Short-term investments
Non-current assets (used for more than one year):
  • Fixed assets (buildings, machinery, equipment)
  • Intangible assets (brands, patents, software)
  • Long-term investments
  • Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets Applied Molecular Transport

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
107 M 214 M 140 M 38.5 M 23.2 M - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
214 M 23.2 M 105 M

Quarterly Total Assets Applied Molecular Transport

2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
20 M 25 M 83.3 M 107 M 125 M - 182 M 214 M 207 M 224 M 126 M 140 M 140 M 140 M 140 M 38.5 M 38.5 M 38.5 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
224 M 20 M 117 M

Total Assets of other stocks in the Biotechnology industry

Issuer Total Assets Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
2.03 B - 2.43 % $ 254 M germanyGermany
Nanobiotix S.A. Nanobiotix S.A.
NBTX
67.8 M $ 30.34 -0.82 % $ 286 B franceFrance
I-Mab I-Mab
IMAB
6.33 B - - $ 866 M chinaChina
AlloVir AlloVir
ALVR
122 M - 4.14 % $ 49.1 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
18.1 B - - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
151 M - 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
12 M - -13.47 % $ 169 M franceFrance
Applied Therapeutics Applied Therapeutics
APLT
54.8 M - - $ 8.42 M usaUSA
BioNTech SE BioNTech SE
BNTX
22 B $ 95.5 3.83 % $ 27.2 B germanyGermany
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
15.2 M - -1.52 % $ 24.7 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
9.51 M $ 2.92 -0.34 % $ 6.35 B israelIsrael
Midatech Pharma plc Midatech Pharma plc
MTP
18.2 M - -18.52 % $ 27.3 M britainBritain
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
1.63 B $ 20.37 -2.4 % $ 952 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
109 M - -24.86 % $ 820 K usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
1.51 B - - - russiaRussia
Adverum Biotechnologies Adverum Biotechnologies
ADVM
180 M - - $ 86.2 M usaUSA
Advaxis Advaxis
ADXS
16.6 M - -9.65 % $ 45.9 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
21.4 M - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
6.95 M - -10.17 % $ 12.2 K usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
583 M $ 32.24 -4.1 % $ 2.14 B usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
778 M - - $ 1.01 B usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
377 M $ 1.4 -0.71 % $ 360 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
66.7 M - - $ 26.5 M usaUSA
Allakos Allakos
ALLK
244 M - - $ 28.6 M usaUSA
Aptinyx Aptinyx
APTX
66.7 M - -39.0 % $ 4.57 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
160 M $ 4.08 -2.16 % $ 436 M usaUSA
Aravive Aravive
ARAV
62.2 M - -13.39 % $ 1.45 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
433 M $ 24.21 -1.47 % $ 3.08 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
113 M - 1.93 % $ 17.4 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
589 M $ 1.49 1.36 % $ 397 M britainBritain
Aptose Biosciences Aptose Biosciences
APTO
10 M - -45.71 % $ 1.2 M canadaCanada
Cidara Therapeutics Cidara Therapeutics
CDTX
215 M - - $ 1.41 B usaUSA
AVROBIO AVROBIO
AVRO
101 M - 1083.1 % $ 745 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
7.77 M - - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
124 M $ 2.55 -0.78 % $ 16 M usaUSA
InflaRx N.V. InflaRx N.V.
IFRX
55.2 M $ 1.0 -2.91 % $ 152 M germanyGermany
AstraZeneca PLC AstraZeneca PLC
AZN
114 B - - $ 96.9 B britainBritain
Immutep Limited Immutep Limited
IMMP
157 M $ 0.31 -2.52 % $ 1.08 B australiaAustralia
Akero Therapeutics Akero Therapeutics
AKRO
826 M - - $ 3.67 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
1.16 B - - $ 867 M germanyGermany
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
1.02 M - -2.5 % $ 5.88 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
8.19 B - 0.49 % $ 251 B cayman-islandsCayman-islands
Akouos Akouos
AKUS
279 M - 0.23 % $ 488 M usaUSA
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
47.9 M $ 3.83 -2.3 % $ 258 B britainBritain
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
34.8 M - 3.16 % $ 1.9 M usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
20 M $ 0.81 -1.16 % $ 27.9 M israelIsrael
Baudax Bio Baudax Bio
BXRX
10 M - 0.59 % $ 63 K usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
287 M - - $ 2.17 B usaUSA
Cabaletta Bio Cabaletta Bio
CABA
165 M $ 3.13 -1.26 % $ 315 M usaUSA